Related Experiment Video
Updated: Aug 11, 2025
06:07
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
2.5K
New Drug: Tirzepatide (Mounjaro™)
1Harding University College of Pharmacy, Searcy, Arkansas.
The Senior Care Pharmacist
|February 8, 2023
Summary
Tirzepatide, a new dual GIP and GLP-1 receptor agonist, shows potent glucose lowering and weight loss for type 2 diabetes management. Its effectiveness and safety profile are comparable to existing GLP-1 therapies.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) is a widespread, progressive condition affecting millions.
- Many T2DM patients struggle to reach target blood glucose levels with current treatments.
- Glucagon-like peptide 1 (GLP-1) receptor agonists are recommended early for T2DM management due to benefits in glycemic control, weight reduction, and cardiovascular outcomes.
Purpose of the Study:
- To provide an overview of tirzepatide, a novel dual GIP and GLP-1 receptor agonist.
- To summarize the findings from the SURPASS clinical trials investigating tirzepatide's efficacy and safety.
Main Methods:
- Review of evidence from five key SURPASS clinical trials.
- Analysis of tirzepatide's impact on glycemic control and body weight.
- Comparison of tirzepatide's adverse effects with GLP-1 receptor agonists.
Main Results:
- Tirzepatide demonstrated potent glucose-lowering effects in T2DM patients.
- Significant weight reduction was observed in patients treated with tirzepatide.
- Adverse effects associated with tirzepatide were comparable to those of GLP-1 receptor agonists.
Conclusions:
- Tirzepatide represents a promising therapeutic option for T2DM management.
- The dual GIP and GLP-1 receptor agonism of tirzepatide offers significant benefits for glycemic control and weight loss.
- Clinical trial data support tirzepatide's role as an effective treatment with a manageable safety profile.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
205
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
205
01:29Drugs for Treatment of Ulcerative Colitis in IBD
212
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
212
01:23Dipeptidyl Peptidase 4 Inhibitors
225
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
225
01:17Drugs for Treatment of Diarrhea-Predominant IBS
256
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
256
01:23Antidepressant Drugs: MAOIs and Other Agents
294
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
294
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
229
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
229